Evidence map›Paper›PMID 34715822›Full record

Trial reportBMC cancer2021

Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.

F J Hinsenveld, B J Noordman, J L Boormans, J Voortman, G J L H van Leenders, S L van der Pas, S C van Beek, D E Oprea-Lager, A N Vis

Open access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Liquid biopsy in bladder cancer: towards precision oncology.Journal of translational medicine · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

F J HinsenveldDepartment of Urology, Amsterdam University Medical Centers, VU University, Postbus 7057, 1007, MB, Amsterdam, internal post address 4F-28, The Netherlands. f.hinsenveld@amsterdamumc.nl.ORCID http://orcid.org/0000-0002-8023-6640
B J NoordmanDepartment of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
J L BoormansDepartment of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
J VoortmanDepartment of Medical Oncology, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.
G J L H van LeendersDepartment of pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
S L van der PasDepartment of Epidemiology and Biostatistics, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.
S C van BeekDepartment of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
D E Oprea-LagerDepartment of Radiology & Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.
A N VisDepartment of Urology, Amsterdam University Medical Centers, VU University, Postbus 7057, 1007, MB, Amsterdam, internal post address 4F-28, The Netherlands.
Amsterdam University Medical Centers · NLErasmus MC · NL

Funding

KWF Kankerbestrijding 12432
6 · The paper itself

Abstract

backgroundThe recommended treatment for patients with non-metastatic muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). Following NAC, 20-40% of patients experience a complete pathological response (pCR) in the RC specimen and these patients have excellent long-term overall survival. Subject to debate is, however, whether patients with a pCR to NAC benefit from RC, which is a major surgical procedure with substantial morbidity, and if these patients might be candidates for close surveillance instead. However, currently it is not possible to accurately identify patients with a pCR to NAC in whom RC might be withheld. The objective of this study is to assess whether pathological response in the RC specimen after NAC can be predicted based on clinical, radiological, and histological variables and on a wide set of molecular biomarkers assessed in tissue, blood and urine.

methodsThis is a multicentre, prospective cohort study, including patients with cT2a-T4a N0-N1 M0 urothelial cell MIBC who are scheduled to undergo cisplatin-based NAC followed by RC. Prior to start of therapy, a 2-Deoxy-2-[18F] fluorodeoxyglucose ( DISCUSSION: If the PRE-PREVENCYS trial shows that the absence of residual disease after NAC in patients with MIBC is accurately predicted, a randomized controlled trial is scheduled comparing the overall survival of NAC plus RC versus NAC followed by close surveillance for patients with a clinically complete response (PREVENCYS trial).

trial registrationNetherlands Trial Register: NL8678; Registered 20 May 2020 https://www.trialregister.nl/trial/8678.

Indexed as

CystectomyOrgan Sparing TreatmentsAlgorithmsCarcinoma, Transitional CellChemotherapy, AdjuvantCisplatinCombined Modality TherapyFluorodeoxyglucose F18HumansNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm, ResidualPositron Emission Tomography Computed TomographyProspective StudiesRadiopharmaceuticalsTomography, X-Ray ComputedCisplatinFluorodeoxyglucose F18RadiopharmaceuticalsBladder cancerBladder-sparingCancer biomarkersCystectomyNeoadjuvant chemotherapyResidual tumour

Identifiers

PMID34715822
PMCPMC8556888
OpenAlexW3208354111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.